<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01597531</url>
  </required_header>
  <id_info>
    <org_study_id>ECDOI-D71</org_study_id>
    <nct_id>NCT01597531</nct_id>
  </id_info>
  <brief_title>Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding</brief_title>
  <official_title>LIRAGLUTIDE AND ORLISTAT TREATMENT FOR PERSISTENT TYPE 2 DIABETES AFTER GASTRIC BANDING: A PILOT STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>East Carolina University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>East Carolina University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether addition of 1 or 2 medicines after gastric&#xD;
      banding can improve remission of type 2 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Liraglutide and Orlistat improve glycemic control by increasing glucagon-like-peptide-1&#xD;
      (GLP-1) response and fat malabsorption, respectively but do not reverse type 2 diabetes.&#xD;
      Roux-en-y gastric bypass (RYGB) surgery reverses type 2 diabetes 84% of the time while the&#xD;
      less invasive, reversible laparoscopic adjustable gastric banding (LAGB) procedure reverses&#xD;
      type 2 diabetes 48% of the time.&#xD;
&#xD;
      Decreased caloric intake occurs after RYGB and LAGB but increased post-prandial GLP-1&#xD;
      response and fat malabsorption only occur after RYGB. Since FDA-approved agents Liraglutide&#xD;
      and Orlistat increase GLP-1 response and fat malabsorption, respectively, it is of&#xD;
      significant clinical interest to determine if addition of Liraglutide and/or Orlistat can&#xD;
      improve type 2 diabetes remission rates in the 52% of patients who have not achieved diabetes&#xD;
      reversal after gastric banding.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty recruiting patients&#xD;
  </why_stopped>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Type 2 diabetes remission</measure>
    <time_frame>baseline, 1 and 4 months post-randomization</time_frame>
    <description>Hemoglobin a1c will be used to assess type 2 diabetes remission.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Whole body insulin sensitivity</measure>
    <time_frame>baseline, 1 and 4 months post-randomization</time_frame>
    <description>Minimal model testing will be used to assess whole body insulin sensitivity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GLP-1 response</measure>
    <time_frame>Baseline, 1 and 4 months post-randomization</time_frame>
    <description>A mixed meal challenge will be used to assess meal-stimulated GLP-1 response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First Phase Insulin secretion</measure>
    <time_frame>Baseline, 1 and 4 months post-randomization</time_frame>
    <description>Minimal model testing will be used to assess first phase insulin secretion.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Gastric Banding</condition>
  <arm_group>
    <arm_group_label>Liraglutide only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Orlistat only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide + Orlistat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>Liraglutide will be started at 0.6 mg injected subcutaneously daily for 1 week and then increased as tolerated to 1.2 mg and then a 1.8 mg daily.</description>
    <arm_group_label>Liraglutide only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orlistat</intervention_name>
    <description>Orlistat will be started initially at a dose of 60 mg taken with the evening meal. Additional doses will be added at breakfast or lunch every 1-2 weeks as tolerated. The patient will be advised to skip drug dosing if little or no fat is contained in the meal. Target dose will 60 mg three times a day and the patients will be advised to take a multivitamin 2 hours before or after Orlistat addition to ensure adequate nutrition.</description>
    <arm_group_label>Orlistat only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide + Orlistat</intervention_name>
    <description>Liraglutide will be started at 0.6 mg injected subcutaneously daily for 1 week and then increased as tolerated to 1.2 mg and then a 1.8 mg daily. Patients not tolerating a higher dose will be allowed to remain on the lower dose as long they tolerate the lower. Following titration of Liraglutide to a maximum tolerated dose, Orlistat will be started initially at a dose of 60 mg taken with evening meal. Additional doses will be added at breakfast or lunch every 1-2 weeks as tolerated. The patient will be advised to skip drug dosing if little or no fat is contained in the meal. Target dose will 60 mg three times a day.</description>
    <arm_group_label>Liraglutide + Orlistat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects will be eligible if they meet the following criteria:&#xD;
&#xD;
          -  male or female,&#xD;
&#xD;
          -  age 25-70 years,&#xD;
&#xD;
          -  BMI 26-65,&#xD;
&#xD;
          -  type 2 diabetic,&#xD;
&#xD;
          -  weight stable for 3 months,&#xD;
&#xD;
          -  status post laparoscopic adjustable gastric banding (LAGB) for at least 1 year,&#xD;
&#xD;
          -  hemoglobin a1c 7-10%;&#xD;
&#xD;
          -  on any diabetic regimen including insulin except for thiazolidinedione use in the past&#xD;
             6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects will be excluded if they meet any of the following criteria:&#xD;
&#xD;
          -  prior history of pancreatitis,&#xD;
&#xD;
          -  prior history of gastroparesis,&#xD;
&#xD;
          -  glomerular filtration rate (GFR) &lt; 50,&#xD;
&#xD;
          -  history of thyroid cancer/multiple endocrine neoplasia/thyroid nodules/medullary&#xD;
             thyroid cancer,&#xD;
&#xD;
          -  history of cholelithiasis,&#xD;
&#xD;
          -  history of hyperoxaluria or calcium oxalate nephrolithiasis,&#xD;
&#xD;
          -  abnormal AST,&#xD;
&#xD;
          -  ALT elevation,&#xD;
&#xD;
          -  current or past history of liver disease,&#xD;
&#xD;
          -  history of Roux-en-y gastric bypass or gastric sleeve or any other bariatric procedure&#xD;
             other than LAGB,&#xD;
&#xD;
          -  type 1 diabetes,&#xD;
&#xD;
          -  any gastrointestinal disease causing malabsorption (including but not limited to&#xD;
             inflammatory bowel disease, celiac sprue),&#xD;
&#xD;
          -  prior history of Orlistat or incretin therapy use in past 3 months,&#xD;
&#xD;
          -  unwilling or unable to complete scheduled testing,&#xD;
&#xD;
          -  thiazolidinedione use within past 6 months,&#xD;
&#xD;
          -  any serious and/or unstable medical, psychiatric, or other condition(s) that prevents&#xD;
             the patient from providing informed consent or complying with the study.&#xD;
&#xD;
        Patients who have had organ transplantation are on chronic anticoagulation, pregnant or&#xD;
        have A1C values &gt; 10% will also be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brody School of Medicine at East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>28590</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP, Sledge I. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009 Mar;122(3):248-256.e5. doi: 10.1016/j.amjmed.2008.09.041. Review.</citation>
    <PMID>19272486</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>May 10, 2012</study_first_submitted>
  <study_first_submitted_qc>May 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2012</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>East Carolina University</investigator_affiliation>
    <investigator_full_name>Moahad S Dar</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Liraglutide</keyword>
  <keyword>Orlistat</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Orlistat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

